Adjuvia Therapeutics
Summary active Updated Jul 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Adjuvia Therapeutics is a preclinical biotechnology company developing oral therapeutics designed to repair mitochondrial damage by simultaneously addressing oxidative stress, chronic inflammation, and organ degeneration 12. Its lead candidate, ATI-105, is a blood-brain-barrier-penetrant lipid nanoparticle formulation of a novel astaxanthin molecule targeting mitochondrial dysfunction 13. On 2026-07-28, Adjuvia closed an $8 million Series Seed financing led by JLO Ventures with participation from Portfolia Ventures and biopharma industry leaders; proceeds will fund an IND filing for ATI-105 later in 2026 and a Phase 1 healthy-volunteer trial in Fall 2026, followed by a Phase 1/2 study in Friedreich’s ataxia patients in early 2027 123.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-28 | Series Seed | $8M | JLO Ventures | Portfolia Ventures 123 |
What Investors Say
No independently sourced investor commentary quoted at press time.
What Founders Say
No independently sourced founder quotes located at press time.
Sources
-
BioSpace, “Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic,” July 28, 2026. Accessed July 30, 2026. https://www.biospace.com/press-releases/adjuvia-therapeutics-closes-8-million-series-seed-financing-to-advance-novel-mitochondrial-disease-therapy-into-the-clinic↩↩↩↩
-
Business Wire, “Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic,” July 28, 2026. Accessed July 30, 2026. https://www.businesswire.com/news/home/20260728578441/en/Adjuvia-Therapeutics-Closes-%248-Million-Series-Seed-Financing-to-Advance-Novel-Mitochondrial-Disease-Therapy-into-the-Clinic↩↩↩
-
Pulse 2.0, “Adjuvia Therapeutics Raises $8 Million Series Seed To Advance ATI-105 Into Clinical Trials,” July 28, 2026. Accessed July 30, 2026. https://pulse2.com/adjuvia-therapeutics-raises-8-million-series-seed-to-advance-ati-105-into-clinical-trials/↩↩↩